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Household transmission of Neisseria meningitidis in the 
meningitis belt
The epidemiology of Neisseria meningitidis is dynamic, 
with risk of meningococcal disease varying widely 
by region and depending on a conﬂ uence of host, 
organism, and environmental factors. Because 
transmission of N meningitidis results mainly in 
asymptomatic carriage, evaluation of oropharyngeal 
carriage can be helpful to understand the epidemiology 
and transmission of N meningitidis and, in turn, 
develop strategies for the prevention and control of 
meningococcal disease. The bacterium is transmitted 
through respiratory droplets and close contact, with 
transmission increasing in crowded settings such as 
military camps, universities, and schools.1 Household 
contacts of patients with meningococcal disease have 
been shown to be at increased risk of meningococcal 
carriage and disease in developed countries, where 
incidence of meningococcal disease is low and outbreaks 
infrequent. However, less is known about household 
transmission dynamics of N meningitidis in the unique 
epidemiological context of the meningitis belt of sub-
Saharan Africa, which is characterised by high rates 
of endemic disease, annual outbreaks, and periodic 
large-scale epidemics, historically due to serogroup A 
meningococci.2 
In The Lancet Global Health, Caroline Trotter and 
colleagues3 describe the importance of household 
transmission of N meningitidis in the meningitis 
belt using data from a series of cross-sectional 
meningococcal carriage surveys held across seven 
countries to describe meningococcal carriage and 
impact of a novel meningococcal serogroup A conjugate 
vaccine (MenAfriVac; Serum Institute of India PVT, 
Pune, India). Within the study the investigators 
recruited a subset of 184 households containing 
putative N meningitidis carriers due to any serogroup for 
longitudinal household carriage surveys carried out over 
6 months. 133 households with conﬁ rmed index carriers 
were compared with 51 control households in which 
N meningitidis in the putative index carrier was ruled 
out by reference testing. 21% (152 of 739) of individuals 
within index carrier households subsequently acquired 
N meninigitidis compared with 9% (35 of 371) of 
individuals in control households. Due to a paucity 
of serogroup A carriers, the impact of MenAfriVac 
vaccination on carriage acquisition or loss within 
households could not be determined. Although the 
overall carriage acquisition rate was 2·4% per month 
(95% CI 1·6–4·0), rates among all age groups were 
four-to-ﬁ ve-times higher in households with an index 
carrier. Overall, the mean duration of carriage was 
3·4 months (2·7–4·4). Index carriers were most likely 
to be adolescents, with a median age of 12 years, and 
children younger than 5 years were most likely to acquire 
carriage. In index carrier households, most individuals 
that subsequently developed carriage acquired the same 
or a similar strain as the index carrier, providing evidence 
for within-household transmission, although external 
acquisition was also noted. Further analysis of the 
strains with next-generation sequencing will be useful 
to further diﬀ erentiate transmission within households 
versus external acquisition.
Since the progressive introduction of the meningococcal 
serogroup A conjugate vaccine in meningitis belt 
countries via mass vaccination campaigns of 1–29 year 
olds starting in 2010, a remarkable eﬀ ect of the vaccine 
has been observed.4 Similar to other conjugate vaccines, 
MenAfriVac has demonstrated the ability to markedly 
reduce serogroup A N meningitidis carriage prevalence and 
generate herd immunity, likely contributing to the near-
elimination of serogroup A disease in vaccinated areas.5,6 
However, epidemics due to other serogroups, such as 
the 2015 serogroup C epidemics in Niger and Nigeria,7,8 
continue to occur. Thus, additional strategies for the 
control of meningococcal disease are needed.
The ﬁ ndings of Trotter and colleagues3 provide further 
insight into transmission dynamics of N meningitidis 
within households in the meningitis belt. However, 
the low sensitivity rate of oropharyngeal swabbing 
(estimated as 57·8% [95% CI 53·5–62·0] in this study) is a 
limitation. Nevertheless, results of this evaluation along 
with surveillance data suggest that targeting school-age 
children and adolescents for vaccination with conjugate 
vaccines could provide maximum beneﬁ t in terms of 
direct protection and generation of herd immunity. 
Further household carriage evaluations speciﬁ cally 
carried out during epidemics are needed to assess 
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the relative importance of household transmission in 
the setting of widespread community transmission. 
Antibiotic chemoprophylaxis of household members 
of meningococcal disease cases is recommended in the 
meningitis belt outside of outbreaks,9 although is rarely 
practiced due to resource and logistical constraints. 
Even though no known cases of meningococcal disease 
were reported in households participating in the study 
from Trotter and colleagues, the increased rate of 
subsequent carriage in index households supports this 
recommendation and eﬀ orts to improve its uptake. 
Additional evaluation of carriage among household 
contacts of a meningococcal case in both outbreak and 
non-outbreak settings would provide additional data to 
inform antibiotic chemoprophylaxis recommendations 
in the meningitis belt. 
Despite the early successes of the MenAfriVac vaccine, 
endemic disease and epidemics due to serogroups C, W, 
and X continue to occur. Additional carriage evaluations 
will be helpful to continue to monitor the impact 
of MenAfriVac on serogroup A carriage as well as to 
support the development and evaluation of additional 
strategies for the control of meningococcal disease in 
this region.
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